Baxter Receives FDA Approval for Gammagard Liquid
- By BSTQ Staff
Baxter International has received U.S. Food and Drug Administration approval for subcutaneous administration of Gammagard Liquid 10% (immune globulin infusion [human]) for patients with primary immunodeficiency. According to Richard Schiff, Baxter’s gammaglobulin trials medical director, “Building upon years of strong clinical data of Gammagard Liquid, our subcutaneous clinical trial in patients with PI demonstrated efficacy consistent with that seen in other clinical studies of intravenous and subcutaneous immune globulin.” Gammagard Liquid is indicated as replacement therapy for primary humoral immunodeficiency in adult and pediatric patients 2 years of age and older.